Veraxa biotech and voyager acquisition corp. announce business combination agreement to create nasdaq-listed biopharmaceutical company advancing a pipeline of next-generation cancer therapies

Zurich, switzerland, and brooklyn, new york, april 23, 2025 (globe newswire) -- veraxa biotech ag (“veraxa” or the “company”), an emerging leader in designing novel cancer therapies, and voyager acquisition corp., a cayman islands exempted company and special purpose acquisition company targeting the healthcare sector (nasdaq: vach, “voyager” or the “spac”), announced today that they have entered into a definitive business combination agreement (the "business combination agreement"). the proposed business combination (the "business combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. upon closing of the transaction, veraxa biotech ag is expected to list on nasdaq under the proposed ticker symbol “verx.”
NDAQ Ratings Summary
NDAQ Quant Ranking